ClinicalTrials.gg
Not yet recruitingNCT07797153Updated Sep 1, 2026

JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer

A Phase 3 interventional study of JSKN033 and Docetaxel in Recurrent or Metastatic Cervical Cancer, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Not yet recruiting at 2 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Primary conditionUterine Cervical NeoplasmsRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Uterine Cervical Neoplasms
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Uterine Cervical Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
368
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
79th of 360
368 · median 90
Started
2026
with 24 others
Phase 3
56 of 455
21 open now
Primary completion
2028-12
later than 221 of 239 live
Registered
449th of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 79th largest by planned enrollment of the 360 interventional ones that give a count, is one of 25 that started in 2026, is one of 56 in phase 3, reaches primary completion later than 221 of the 239 other live ones, and was the 449th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 243 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN033 versus investigator's choice of chemotherapy in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and PD-1/L1 inhibitor therapy.

03

Conditions studied

  • Recurrent or Metastatic Cervical Cancer

Browse trials for

04

In context

Uterine Cervical Neoplasms Reclassified

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 677 are open to participants now.

This study's planned enrollment of 368 is above the median of 100 across 1,738 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd is the lead sponsor of 38 studies on the registry; 16 are open to participants now.

Compared within Uterine Cervical Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary participation and written .
  • ≥18 years;
  • performance status score of 0 or 1.
  • Expected survival of more than 3 months.
  • or cytologically confirmed recurrent or cervical cancer.
  • At least one in the baseline.
  • Adequate organ function.
  • Provide primary or metastatic tumor samples.
  • Capable and willing to comply with the study protocol, treatment plan, laboratory tests, and other related study procedures.

Exclusion criteria

Exclusion Criteria:

  • Tumors with histologic components other than squamous-cell carcinoma and adenocarcinoma.
  • Other- diagnosed within 3 years prior to randomization.
  • Active central nervous system .
  • Baseline imaging showing tumor invasion, compression of, or arising from vital organs.
  • Prior treatment with topoisomerase I inhibitors or topoisomerase I inhibitor based antibody-drug conjugates.
  • Inadequate washout from prior therapy before randomization.
  • Risk factors for ILD.
  • Significant cardiovascular or cerebrovascular disease.
  • Clinically-significant gastrointestinal abnormalities.
  • History of genital-tract fistula.
  • Uncontrolled pleural effusion.
  • Active or prior -disease .
  • Uncontrolled infection.
  • Toxicity from previous anti-cancer treatments not recovered to Grade ≤1.
  • History of ≥Grade 3 immune-related adverse events irAEs.
  • Previous allogeneic bone-marrow or solid organ transplantation.
  • Allergic reactions or to any component of JSKN033 or the assigned chemotherapy agent.
  • Pregnant or lactating female participants, or women planning pregnancy during the study.
  • Conditions affecting study drug treatment safety or compliance, including psychiatric disorders, alcohol abuse, or drug abuse.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
368 participants (estimated)

Study arms

  • Experimental
    Experimental

    JSKN033

    Drug: JSKN033

  • Active comparator
    Active Comparator

    Investigator's Choice of Chemotherapy: Docetaxel, Topotecan, Gemcitabine or Pemetrexed.

    Drug: Docetaxel · Drug: Topotecan · Drug: Gemcitabine (GEM) · Drug: Pemetrexed

Interventions

07

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) assessed by Blinded Independent Review Committee (BIRC) as per RECIST 1.1

    PFS was defined as the time from randomization until the date of progressive disease or death, whichever occurred first

    Time frame: Up to approximately 27 months

  2. Overall Survival (OS)

    OS was defined as the time from randomization until the date of death from any cause

    Time frame: Up to approximately 27 months

Secondary outcomes

  1. Overall Response Rate (ORR) evaluated by BIRC as per RECIST 1.1

    ORR was defined as the proportion of subjects achieving Complete Response (CR) or Partial Response (PR)

    Time frame: Up to approximately 27 months

  2. Duration of Response (DoR) evaluated by BIRC as per RECIST 1.1

    DOR was defined as the time from CR/PR to PD or death from any cause, whichever occurs first

    Time frame: Up to approximately 27 months

  3. Disease Control Rate (DCR) evaluated by BIRC as per RECIST 1.1

    DCR was defined as the proportion of subjects whose best overall response is CR, PR, or Stable Disease (SD)

    Time frame: Up to approximately 27 months

  4. PFS evaluated by the Investigator as per RECIST 1.1

    PFS was defined as the time from randomization until the date of progressive disease or death, whichever occurred first

    Time frame: Up to approximately 27 months

  5. ORR evaluated by the Investigator as per RECIST 1.1

    ORR was defined as the proportion of subjects achieving Complete Response (CR) or Partial Response (PR)

    Time frame: Up to approximately 27 months

  6. DoR evaluated by the Investigator as per RECIST 1.1

    DOR was defined as the time from CR/PR to PD or death from any cause, whichever occurs first

    Time frame: Up to approximately 27 months

  7. DCR evaluated by the Investigator as per RECIST 1.1

    DCR was defined as the proportion of subjects whose best overall response is CR, PR, or Stable Disease (SD)

    Time frame: Up to approximately 27 months

  8. Number and Severity of Treatment-emergent Adverse Events (TEAEs)

    The incidence and severity of TEAEs and TRAEs (Treatment-related Adverse Events, graded according to NCI CTCAE 5.0), Serious AEs (SAEs), laboratory tests, etc.

    Time frame: Up to approximately 27 months

  9. Patient-reported Quality of Life-European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    Patient-reported quality-of-life assessments using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). All scores are transformed to a 0-100 scale. Higher scores represent better function/global quality-of-life status for functional and global health scales, and worse symptom burden for symptom scales.

    Time frame: Up to approximately 27 months

  10. Patient-reported Quality of Life- European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer 24 (EORTC QLQ-CX24)

    Patient-reported quality-of-life assessments using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer 24 (EORTC QLQ-CX24). All scores are transformed to a 0-100 scale; higher scores indicate worse outcomes for symptom scales, except for sexual activity and sexual enjoyment items where higher scores indicate better outcomes.

    Time frame: Up to approximately 27 months

  11. Plasma Concentrations of JSKN003

    Measurement of plasma concentrations of JSKN003.

    Time frame: Up to approximately 27 months

  12. Plasma Concentration of Total Antibody

    Measurement of plasma concentration of total antibody.

    Time frame: Up to approximately 27 months

  13. Plasma Concentration of Free Payload

    Measurement of plasma concentration of free payload.

    Time frame: Up to approximately 27 months

  14. Plasma Concentration of Envotumab

    Measurement of plasma concentration of envotumab.

    Time frame: Up to approximately 27 months

  15. Incidence and Titer of Anti-Drug Antibodies

    Assessment of the incidence and titer of anti-drug antibodies, as applicable.

    Time frame: Up to approximately 27 months

  16. Incidence and Titer of Neutralizing Antibodies

    Assessment of the incidence and titer of neutralizing antibodies, as applicable.

    Time frame: Up to approximately 27 months

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.

Of 46 industry-sponsored phase 3 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 55. This study's planned 27 months is below that.

Counting every sponsor, half of 99 studies reached it within 55 months; a quarter within 24 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Sep 1, 2026
StartEst.
Sep 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07797153
Responsible party
Sponsor
First posted
Sep 1, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Sep 1, 2026

Study contacts

Xiaohua Wu, Doctor
Contact
wu.xh@fudan.edu.cn
086-021-64175590

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JSKN033

Start the discussion